Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
(→ATC) |
(→Links) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 13: | Line 13: | ||
==Links== | ==Links== | ||
[http://www.scielo.br/pdf/ag/v51n3/0004-2803-ag-51-03-255.pdf Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?] | [http://www.scielo.br/pdf/ag/v51n3/0004-2803-ag-51-03-255.pdf Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?] | ||
==ATC== | ==[[ATC]]== | ||
Lipid modifying agents | Lipid modifying agents | ||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | {| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | ||
Latest revision as of 15:21, 25 October 2024
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. This fibrate reduces triglyceride and rises HDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cirrhosis (See Figure in gallery).
Links
Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?
ATC
Lipid modifying agents
